TENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT
Exhibit 10.10
TENTH AMENDED AND RESTATED
THIS TENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is entered into on September 2, 2004 among ALSIUS CORPORATION, a California corporation (the “Company”), and certain investors in the Company listed on Exhibit A hereto (as it may be amended from time to time pursuant to the terms hereof) (“Investors”).
WITNESSETH:
WHEREAS, pursuant to the Restated Articles (as defined in that certain Series F Preferred Stock Purchase Agreement, dated as of the date hereof, among the Company and such Investors named therein (the “Series F Agreement”)), the outstanding shares of Series C-1, Series C-2 and Series D Preferred Stock have been reclassified into shares of Series C-D Preferred Stock;
WHEREAS, certain of the Investors hold shares of the Company’s Common Stock, Series A, Series B, Series C-D, Series E and/or Series F Preferred Stock (the “Prior Parties”) and possess registration rights, information rights, rights of first refusal, and other rights pursuant to that certain Ninth Amended and Restated Investor Rights Agreement, dated as of December 23, 2003, between the Company, such Investors and certain other shareholders of the Company (the “Ninth Restated Agreement”);
WHEREAS, on the date hereof, CHANNEL Medical Partners, L.P. (“CHANNEL”), Canaan Equity II L.P., Canaan Equity II L.P. (QP) and Canaan Equity II Entrepreneurs LLC (“Canaan”) and other existing Investors are purchasing Series F Preferred Stock of the Company pursuant to a Series F Agreement;
WHEREAS, it is a condition to the obligations of CHANNEL and Canaan that this Agreement be executed by the parties hereto, and the parties are willing to execute, and to be bound by the provisions of, this Agreement;
WHEREAS, the undersigned Prior Parties desire to terminate the Ninth Restated Agreement and to accept on behalf of themselves and all other Investors, the rights created pursuant hereto in lieu of the rights granted to them under the Ninth Restated Agreement;
WHEREAS, the Investors and the Company are executing this Agreement to, among other things, amend Section 2.3(b) of the Ninth Restated Agreement to change the number of shares of Common Stock that may be issued to employees, officers, directors and consultants from 900,000,000 shares to 2,100,000 shares to reflect the 500-for-1 reverse split of the Company’s capital stock effected on March 22, 2004 and an increase in the number of authorized shares reserved for issuance to employees, officers, directors and consultants, to amend Section 3.6 of the Ninth Restated Agreement to clarify the requirements to amend the agreement, to reflect the reclassification of the Series C-1, Series C-2 and Series D Preferred Stock into Series C-D Preferred Stock, to make certain other changes to the Ninth Restated Agreement in connection with the sale of the Series F Preferred Stock to CHANNEL and Canaan, and to make CHANNEL and Canaan parties to the Ninth Restated Agreement; and
WHEREAS, the Investors executing this Agreement hold a majority of the shares held by all investors who are party to the Ninth Restated Agreement and a majority of the shares of Series C-D, Series E and Series F Preferred Stock or Common Stock issuable upon conversion thereof, and therefore, have the power under Section 3.6 of the Ninth Restated Agreement to amend such agreement.
NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties to the Ninth Restated Agreement hereby agree that the Ninth Restated Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows:
SECTION 1
REGISTRATION RIGHTS
1.1 Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings:
“Act” means the Securities Act of 1933, as amended.
“Bridge Notes” shall mean the convertible promissory notes made by the Company, dated April 30, 2003, in connection with a bridge financing of the Company of approximately $3,088,000 and the convertible promissory notes made by the Company, dated November 20, 2003, in connection with a bridge financing of $500,000.
“Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Act.
“Common Stock” shall mean common stock of the Company, no par value.
“Company” shall have the meaning assigned to such term in the Preamble hereto.
“Holder” shall mean any person holding Registrable Securities (or securities convertible into or exchangeable for Registrable Securities) to whom the rights under this Section 1 were granted directly from the Company and any person holding Registrable Securities (or securities convertible into or exchangeable for Registrable Securities) to whom the rights under this Section 1 have been transferred in accordance with Section 1.10 hereof.
“Initiating Holders” shall have the meaning set forth in Section 1.2 hereof.
“Qualified IPO” shall mean a firm underwritten public offering by the Company of its Common Stock, with net proceeds of at least $20,000,000 and with a price per share of at least $0.025 (adjusted for any stock splits, stock dividends or recapitalizations), prior to the deduction of underwriting commissions and offering expenses.
“Registrable Securities” means (i) the Common Stock issued in exchange for the common stock issued by Retroperfusion Systems, Inc. (“RSI”) upon conversion of the RSI Series B, Series C and Series D Preferred Stock and in exchange for the RSI Series E and Series F Preferred Stock, (ii) the Common Stock issued upon exercise of the warrants issued under the Loan and Warrant Subscription Agreements dated on or about August 17, 1993, (iii) the Common Stock issued under the Loan and Warrant Subscription Agreements dated October 1994, (iv) the Common Stock issued or issuable upon conversion of the Series A, Series B, Series C-D, Series E and Series F Preferred Stock (v) the Common Stock issuable upon conversion of the Warrants issued in connection with the Bridge Notes and (vi) any Common Stock of the Company issued or issuable in respect of the above described securities upon any stock split, stock dividend, recapitalization, or similar event, or any Common Stock otherwise issued or issuable with respect to the above described securities; provided, however, that shares of Common Stock or other securities shall not be treated as Registrable Securities for purposes of Section 1 hereof if they have been sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction.
The terms “register,” “registered” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Act, and the declaration or ordering of the effectiveness of such registration statement.
“Registration Expenses” shall mean all expenses, except as otherwise stated below, incurred by the Company in complying with Sections 1.2, 1.3 and 1.4 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses and the expense of any regular or special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).
“Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the securities registered by the Holders.
“Series A Preferred Stock” shall mean the Series A Preferred Stock of the Company acquired pursuant to the Series A Preferred Stock Subscription Agreements of various dates.
“Series B Preferred Stock” shall mean the Series B Preferred Stock of the Company acquired pursuant to the Note Conversion Agreement dated May 31, 1996.
“Series C-D Preferred Stock” shall mean the Series C-D Preferred Stock issued upon exchange of (i) the Series C-1 and Series C-2 Preferred Stock of the Company issued pursuant to the Series C-1 and Series C-2 Preferred Stock Purchase Agreement dated as of March 14, 1997, including 106,250 shares of Series C-1 Preferred Stock issued to Guidant Corporation in exchange for consulting services, (ii) 163,077 shares of Series C-2 Preferred Stock of the Company issued to Guidant Corporation pursuant to the Termination Agreement and Release dated November 1, 1998 by and between the Company and Guidant Corporation (the “Termination and Release”), (iii) the Series C-2 Preferred Stock of the Company issued pursuant to the Series C-2 Agreement and (iv) the Series D Preferred Stock of the Company acquired pursuant to the Series D Preferred Stock Purchase Agreement dated as of May 17, 2000.
“Series E Preferred Stock” shall mean the Series E Preferred Stock of the Company acquired pursuant to the Series E Preferred Stock Purchase Agreement dated as of November 8, 2000, and the Series E Preferred Stock Purchase Agreement dated as of July 17, 2002.
“Series F Preferred Stock” shall mean the Series F Preferred Stock of the Company acquired pursuant to the Series F Preferred Stock Purchase Agreement, dated as of the date of December 23, 2003, or acquired pursuant to the Series F Preferred Stock Purchase Agreement dated as of the date of this Agreement.
“Warrants” means those certain warrants to purchase Common Stock of the Company, dated April 30, 2003, issued to the initial purchasers of the Bridge Notes.
1.2 Requested Registration.
(a) In case the Company shall receive at any time after the earlier of (i) September 1, 2004 and (ii) six (6) months after the effective date of the first registration statement filed by the Company covering an offering of any of its securities to the public, a written request from Holders (“Initiating Holders”) that the Company effect any registration, qualification or compliance with respect to at least forty percent (40%) of the Registrable Securities (or any lesser number of Registrable Securities if the anticipated
aggregate offering price to the public from the proposed sale of such Registrable Securities, net of underwriting discounts and commissions, would exceed $8,000,000), the Company will:
(i) promptly give written notice of the proposed registration, qualification or compliance to all other Holders; and
(ii) as soon as practicable, use its best efforts to effect such registration, qualification or compliance (including, without limitation, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 1.2:
(A) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Act;
(B) During the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on the date one hundred eighty (180) days immediately following the effective date of, any registration statement pertaining to securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective;
(C) After the Company has effected two such registrations pursuant to this Section 1.2(a), and such registrations have been declared or ordered effective; or
(D) If the Company shall furnish to such Holders a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its shareholders for a registration statement to be filed at such time, then the Company’s obligation to use its best efforts to register, qualify or comply under this Section 1.2 shall be deferred for a period not to exceed ninety (90) days from the date of receipt of written request from the Initiating Holders; provided, however, the Company may only defer one registration pursuant to this Section 1.2(a)(ii)(D) in any twelve month period.
Subject to the foregoing clauses (A) through (D), the Company shall file a registration statement covering the Registrable Securities so requested to be registered as soon as practicable, after receipt of the request or requests of the Initiating Holders.
(b) In the event that a registration pursuant to Section 1.2 is for a registered public offering involving an underwriting, the Company shall so advise the Holders as part of the notice given pursuant to Section 1.2(a)(i). In such event, the right of any Holder to registration pursuant to Section 1.2 shall be conditioned upon such Holder’s participation in the underwriting
arrangements required by this Section 1.2, and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested shall be limited to the extent provided herein.
The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders, but subject to the Company’s reasonable approval. Notwithstanding any other provision of this Section 1.2, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be, underwritten, then the Company shall so advise all holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders who have elected to participate in the registration (except those Holders who have indicated to the Company their decision not to distribute any of their Registrable Securities through such underwriting) in proportion, as nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the registration statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares.
If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the managing underwriter and the Initiating Holders. In the event of any such withdrawal, the participating Holders may increase their participation pro rata up to the amount equal to the withdrawn securities.
1.3 Company Registration.
(a) If at any time or from time to time the Company shall determine to register any of its securities, either for its own account or the account of a security holder or holders, other than (i) a registration relating solely to employee benefit plans, or (ii) a registration relating solely to a Commission Rule 145 transaction, the Company will:
(i) promptly give to each Holder written notice thereof; and
(ii) include in such registration (and any related qualification under blue sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within twenty (20) days after receipt of such written notice from the Company, by any Holder.
(b) If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 1.3(a)(i). In such event the right of any Holder to registration pursuant to Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 1.3, if the managing underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the Registrable Securities or other securities to be included in such registration, provided, however, that after the Company’s
initial firm commitment underwritten public offering (the “IPO”) no such limitation shall reduce the percentage of Registrable Securities included in such registration below fifty percent (50%). In the Company’s IPO, such limitation may reduce the percentage of Registrable Securities included in such registration to 0%. The Company shall so advise all Holders and other holders distributing their securities through such underwriting and the number of shares of Registrable Securities and other securities that may be included in the registration and underwriting shall be allocated among all Holders and such other holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities and other securities contractually entitled to registration in the offering held by such Holders and such other holders at the time of filing the registration statement. To facilitate the allocation of shares in accordance with the above provisions, the Company may round the number of shares allocated to any Holder or holder to the nearest 100 shares. If any Holder or holder disapproves of the terms of any such underwriting, he may elect to withdraw therefrom by written notice to the Company and the managing underwriter. In the event of any such withdrawal, the participating Holders may increase their participation pro rata up to the amount equal to the withdrawn securities.
(c) The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration.
1.4 Registration on Form S-3.
(a) If any Holder or Holders request that the Company file a registration statement on Form S-3 (or any successor form to Form S-3) for a public offering of shares of the Registrable Securities the reasonably anticipated aggregate price to the public of which, net of underwriting discounts and commissions, would exceed $1,000,000, and the Company is a registrant entitled to use Form S-3 to register the Registrable Securities for such an offering, the Company shall use its best efforts to cause such Registrable Securities to be registered for the offering on such form and to cause such Registrable Securities to be qualified in such jurisdictions as the Holder or Holders may reasonably request; provided, however, that the Company shall not be required to effect more than one registration pursuant to this Section 1.4 in any twelve (12) month period. In the event that a registration statement pursuant to this Section 1.4 is for a registered public offering involving an underwriting, the substantive provisions of Section 1.2(b) shall be applicable to such registration initiated under this Section 1.4.
(b) Notwithstanding the foregoing, the Company shall not be obligated to take any action pursuant to this Section 1.4: (i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Act; (ii) if the Company, within ten (10) days of the receipt of the request of the Initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the Commission within forty-five (45) days of receipt of such request (other than with respect to a registration statement relating to a Rule 145 transaction, an offering solely to employees or any other registration which is not appropriate for the registration of Registrable Securities); provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and the Registrable Securities which are the subject of the requested registration will be included in such Company initiated registration; or (iii) if the Company shall furnish to such Holder a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its shareholders for a registration statement to be filed at such time, then the Company’s obligation
to use its best efforts to file a registration statement shall be deferred for a period not to exceed ninety (90) days from the receipt of the request to file such registration by such Holder; provided, however, the Company may only defer one registration pursuant to this Section 1.4(b) in any twelve month period.
1.5 Expenses of Registration. All Registration Expenses, excluding underwriting discounts and commissions, incurred in connection with any registration effected pursuant to the terms of Section 1.2, 1.3 and 1.4 hereof, shall be borne by the Company.
However, if any Holder elects to withdraw from an underwriting under Section 1.2 or 1.4, then that Holder shall be responsible for all of its Registration Expenses for that particular registration. All Selling Expenses relating to securities registered on behalf of the Holders and all other registration expenses shall be borne by the Holders of such securities pro rata on the basis of the number of shares so registered.
1.6 Registration Procedures. In the case of each registration, qualification or compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. At its expense the Company will:
(a) Prepare and file with the Commission a registration statement with respect to such securities and use its best efforts to cause such registration statement to become and remain effective for at least one hundred twenty (120) days or until the distribution described in the Registration Statement has been completed; provided, however, in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such one hundred twenty (120) day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment that (A) includes any prospectus required by section 10(a)(3) of the Act or (B) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (A) and (B) above to be contained in periodic reports filed pursuant to section 13 or 15(d) of the Exchange Act (as defined below) in the registration statement.
(b) As promptly as practicable, prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement.
(c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them.
(d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.
(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.
(f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing and as soon as practicable thereafter, prepare and furnish to each Holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing.
(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed.
(h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.
(i) Use its best efforts to comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month after the effective date of any registration statement, which earnings statement shall satisfy the provisions of section 11(a) of the Act.
(j) Furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such date, from the independent accountants of the Company, in form and substance as is customarily given by independent accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities.
1.7 Indemnification.
(a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning of section 15 of the Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of section 15 of the Act, against all expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation by the Company of any federal, state or common law rule or regulation applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder, controlling person or underwriter and stated to be specifically for use therein.
(b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of section 15 of the Act, and each other such Holder, each of its officers and directors and each person controlling such Holder within the meaning of section 15 of the Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use therein. Notwithstanding the foregoing, the liability of each Holder under this subsection (b) shall be limited in an amount equal to the public offering price of the shares sold by such Holder. A Holder will not be required to enter into any agreement or undertaking in connection with any registration under this Section 1.7 providing for any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 1.7(b).
(c) Each party entitled to indemnification under this Section 1.7 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, provided, however, that the Indemnifying Party shall bear the expense of independent counsel for the Indemnified Party if the Indemnified Party reasonably determines that representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interest, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations
under this Section 1.7 unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the Indemnifying Party shall not assume the defense for matters as to which there is a conflict of interest or separate and different defenses. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.
1.8 Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this Section 1.
1.9 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market exists for the Common Stock of the Company, the Company agrees to use its best efforts to:
(a) Make and keep public information available, as those terms are understood and defined in Rule 144 under the Act, at all times after the effective date that the Company becomes subject to the reporting requirements of the Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
(b) Use its best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Act and the Exchange Act (at any time after it has become subject to such reporting requirements);
(c) So long as a Holder owns any Registrable Securities that are “restricted securities” under Rule 144 under the Act, to furnish to the Holder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration.
1.10 Transfer of Registration Rights. The rights to cause the Company to register securities granted Investor under Sections 1.2, 1.3 and 1.4 may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by an Investor provided that: (a) such transfer may otherwise be effected in accordance with applicable securities laws, and (b) such assignee or transferee acquires at least 50,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits’, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the benefit of an Investor or Investor’s immediate family members and any partners of an Investor) or the securities into which they are convertible. Notwithstanding the foregoing, the rights to cause the Company to register securities may be assigned, in connection with a distribution by such Investor, to any partner, former partner, affiliate or the estate of any such partner without compliance with item (b) above, provided written notice thereof is promptly given to the Company.
1.11 Standoff Agreement. Each Holder agrees, so long as such Holder holds at least one percent (1%) of the Company’s outstanding voting equity securities, in connection with an underwritten public offering of the Company’s securities that, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Common Stock of the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days in the case of a Qualified IPO and not to exceed ninety (90) days, or one hundred twenty (120) days if the Holder holds ten percent (10%) of the outstanding stock of the Company, in the case of any other public offering) from the effective date of such registration as may be requested by the underwriters; provided, that all other Holders of at least one percent (1%) of the Company’s outstanding voting equity securities and all of the officers and directors of the Company who own stock of the Company also agree to such restrictions.
1.12 Termination of Registration Rights. No Holder of Registrable Securities shall be entitled to exercise any right provided in this Section 1 after five (5) years following the consummation of a Qualified IPO if such Holder can sell its securities under Rule 144, or any successor rule, without any restriction on volume.
SECTION 2
COVENANTS OF THE COMPANY
2.1 Basic Financial Information. The Company will furnish the following reports to each Holder of at least 400 shares (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the benefit of an Investor or Investor’s immediate family members and any partner of an Investor) of the Company’s Registrable Securities (each a “Significant Holder”):
(a) As soon as practicable after the end of each fiscal year of the Company, and in any event within ninety (90) days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles consistently applied and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and certified by independent public accountants of recognized national standing selected by the Company.
(b) As soon as practicable after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and consolidated statements of income and cash flows of the Company and its subsidiaries for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied and setting forth in comparative form the figures for the corresponding periods of the previous fiscal year and to the Company’s operating plan then in effect and approved by its Board of Directors, subject to changes resulting from normal year-end audit adjustments, all in reasonable detail and certified by the principal financial or accounting officer of the Company, except that such financial statements need not contain the notes required by generally accepted accounting principles.
(c) From the date the Company becomes subject to the reporting requirements of the Exchange Act (which shall include any successor federal statute), and in lieu of the financial information required pursuant to Sections 2.1(a) and (b), copies of its annual reports on Form 10-K and its quarterly reports on Form 10-Q, respectively.
2.2 Additional Information Rights.
(a) The Company will deliver the following reports and other information to each Significant Holder:
(i) As soon as practical after the end of each month and in any event within thirty (30) days thereafter a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such month and consolidated statements of income and cash flows of the Company and its subsidiaries, for each month and for the current fiscal year of the Company to date, all subject to normal year-end audit adjustments, prepared in accordance with generally accepted accounting principles consistently applied and certified by the principal financial or accounting officer of the Company, together with a comparison of such statements to the corresponding periods of the prior fiscal year and to the Company’s operating plan then in effect and approved by its Board of Directors.
(ii) Annually (but in any event at least thirty (30) days prior to the commencement of each fiscal year of the Company) the financial plan of the Company, in such manner and form as approved by the Board of Directors of the Company, which financial plan shall include a projection of income and a projected cash flow statement for such fiscal year and a projected balance sheet as of the end of such fiscal year. Any material changes in such business plan shall be delivered to each Significant Holder as promptly as practicable after such changes have been approved by the Board of Directors of the Company.
(iii) As soon as practicable after each meeting of the Company’s Board of Directors, and in any event within thirty (30) days thereafter, a complete and accurate copy of the minutes of such meeting as recorded by the Secretary of the Company.
(iv) With reasonable promptness, such other information and data with respect to the Company and its subsidiaries that has been furnished to the Company’s Board of Directors.
(b) The provisions of Section 2.1 and this Section 2.2 shall not be in limitation of any rights which any Holder or Significant Holder may have with respect to the books and records of the Company and its subsidiaries, or to inspect their properties or discuss their affairs, finances and accounts, under the laws of the jurisdictions in which they are incorporated.
(c) Anything in Section 2 to the contrary notwithstanding, no Holder or Significant Holder by reason of this Agreement shall have access to any trade secrets or classified information of the Company. Each Significant Holder hereby agrees to hold in confidence and trust and not to misuse or disclose any confidential information provided pursuant to this Section 2. The Company shall not be required to comply with this Section 2.2 in respect of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or greater than ten percent (10%) shareholder of a competitor.
(d) Each Holder who represents to the Company that it is a “venture capital operating company” for purposes of Department of Labor Regulation Section 2510.3-101 shall in addition have the right to consult with and advise the officers of the Company as to the management of the Company.
2.3 Right of Participation.
(a) The Company hereby grants to each Investor holding at least 400 shares (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to family members of an Investor, trusts for the benefit of an Investor or Investor’s immediate family members and any partner of an Investor) of the Company’s Registrable Securities the right of participation to purchase up to its Pro Rata Share, as defined below, of New Securities (as defined in Section 2.3(b)) which the Company may, from time to time, propose to sell and issue. An Investor’s Pro Rata Share, for purposes of this right of participation, is the ratio that the number of shares of Common Stock issued or issuable upon conversion of the Registrable Securities held by such Investor bears to the sum of the total shares of issued and outstanding Common Stock of the Company, including shares of Common Stock issuable upon conversion of outstanding capital stock or other convertible securities other than options or warrants.
(b) Except as set forth below, “New Securities” shall mean any shares of capital stock of the Company including Common Stock and Preferred Stock, whether now authorized or not, and rights, options or warrants to purchase said shares of Common Stock or Preferred Stock, and securities of any type whatsoever that are, or may become, convertible into said shares of Common Stock or Preferred Stock. Notwithstanding the foregoing, “New Securities” shall not include (a) securities issued pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization whereby the Company or its shareholders own not less than fifty-one percent (51%) of the voting power of the surviving or successor corporation, (b) shares of the Company’s Common Stock or securities convertible into Common Stock or related options or warrants exercisable for or convertible into such Common Stock or securities convertible into Common Stock issued to employees, officers and directors of, and consultants pursuant to a plan approved by the Board of Directors of the Company up to an aggregate of 2,100,000 shares (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like), (c) up to five percent (5%) of outstanding capital stock of the Company on a fully diluted basis issued to customers, vendors, licensees, licensors, and equipment lessors of the Company, pursuant to any arrangement approved by the Board of Directors of the Company, (d) shares issued upon conversion of shares of Series A, Series B, Series C-D, Series E or Series F Preferred Stock, (e) shares issued in connection with any stock split or recapitalization by the Company, (f) shares issued as a dividend or distribution on Series A, Series B, Series C-D, Series E or Series F Preferred Stock or (g) shares of Series C-D Preferred Stock issued in connection with the reclassification of the Series C-1, Series C-2 and Series D Preferred Stock.
(c) In the event the Company proposes to undertake an issuance of New Securities, it shall give each Investor written notice of its intention, describing the type of New Securities, and the price and terms upon which the Company proposes to issue the same. Each Investor shall have fifteen (15) days from the date of receipt of any such notice to agree to purchase up to its respective Pro Rata Share of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the maximum quantity of New Securities it will agree to purchase.
(d) In the event an Investor fails to exercise the right of participation to purchase its Pro Rata Share of such New Securities within said fifteen (15) day period, the Company shall offer such shares to the other Investors who have elected to exercise their rights to purchase New Securities. Each such participating Investor shall be entitled to purchase that number of
shares of new securities not being purchased by the non-participating Investor as determined by multiplying such non-purchased New Securities by a fraction, the numerator of which is the number of shares of New Securities being purchased by the participating Investor and the denominator of which is the number of shares of New Securities being purchased by all Investors electing to purchase a portion of the New Securities which would have been sold to the non-participating Investor. Each Investor electing to purchase such non-participating Investor’s New Securities shall have five (5) days from the date of receipt of any notice from the Company with respect thereto to agree to purchase its respective share of such non-participating Investor’s New Securities. Thereafter, the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within sixty (60) days from the date of said agreement) to sell the New Securities not elected to be purchased by Investors at the price and upon the terms no more favorable to the purchasers of such securities then specified in the Company’s notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New Securities within said ninety (90) day period (or sold and issued New Securities in accordance with the foregoing within sixty (60) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities, without first offering such securities in the manner provided above.
(e) The right of participation granted under this Agreement shall expire (a) upon the closing of and does not apply to shares issued in connection with a Qualified IPO and (b) as to each Investor if such Investor (along with affiliated entities of such Investor) no longer holds 400 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like).
(f) The right of participation hereunder may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by an Investor provided that: (a) such transfer may otherwise be effected in accordance with applicable securities laws, and (b) such assignee or transferee acquires at least 50,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits’, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the benefit of an Investor or Investor’s immediate family members and any partners of an Investor) or the securities into which they are convertible. Notwithstanding the foregoing, the rights to cause the Company to register securities may be assigned, in connection with a distribution by such Investor, to any partner, former partner, affiliate or the estate of any such partner without compliance with item (b) above, provided written notice thereof is promptly given to the Company.
2.4 Treatment of Investors.
(a) No Investor will be offered (either directly or indirectly) any consideration or other rights in connection with any amendment, waiver or consent of or under the Company’s articles of incorporation which is not offered to all Investors similarly situated.
(b) No Investor will be offered (either directly or indirectly) any consideration or other rights, except as currently provided under the Ancillary Agreements (as defined in the Series F Agreement), in connection with any amendment or waiver of this Agreement which is not offered to all Investors similarly situated.
SECTION 3
MISCELLANEOUS
3.1 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
3.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California.
3.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
3.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
3.5 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal delivery to the party to be notified by hand or professional courier service, by facsimile upon receipt of confirmation of delivery or five (5) days after deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the Company’s addressed in the case of the Company, or for the Investors, at the address indicated on Exhibit A, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties.
3.6 Amendment and Waivers. Except as may be otherwise provided in Section 3.7, any provision of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company, the Investors holding a majority of the shares held by all Investors, and the Investors holding a majority of the shares of Common Stock issued or issuable upon conversion of Series C-D, Series E and Series F Preferred Stock; provided, however, that any waiver or amendment that adversely affects an Investor in a manner that is materially different than the other Investors (other than differences resulting solely from ownership of a different amount of shares) shall require the written consent of such Investor in order to be binding on such Investor; and, provided further, that the Company may amend Exhibit A to this Agreement at any time and from time to time without the consent of any Investor solely to (i) add CHANNEL and any Rights Investor (as defined in the Purchase Agreement), in each case provided that CHANNEL and such Rights Investor executes a Counterpart to this Agreement in the form of Exhibit B hereto as a party to this Agreement, or (ii) reflect the conversion to Common Stock of the Preferred Stock of any Investor whose Preferred Stock is so converted (voluntarily or automatically) pursuant to the conversion provisions of such Preferred Stock, or to reflect any adjustment to the outstanding shares of Preferred Stock or Common Stock due to a stock split, stock dividend or recapitalization. Any amendment or waiver effected in accordance with this Section shall be binding upon all present and future Investors.
3.7 Additional Registration Rights. The Company will not grant any registration rights not set forth herein without the prior approval of the Holders of more than fifty percent (50%) of the then outstanding Registrable Securities and the Investors holding a majority of the shares of Common Stock issued or issuable upon conversion of Series C-D, Series E and Series F Preferred Stock; provided, however, in the event the Shareholders of the Company have legally and validly approved the sale of securities and the granting of registration rights to the holders thereof, such securities may be added to the definition of Registrable Securities hereunder and such holders shall constitute Holders hereunder to the extent they agree in writing to be bound by the terms and conditions hereof.
3.8 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.
3.9 Effect of Amendment or Waiver. Each Holder acknowledges that by the operation of Section 3.6 hereof less than all of the Holders (or transferees of Registrable Securities) may effect an amendment or waiver of provisions of this Agreement and may therefore diminish or eliminate all rights of such Holder under this Agreement even though such Holder has not consented to the amendment or waiver.
[SIGNATURES ON FOLLOWING PAGE]
| THE COMPANY | ||
| ALSIUS CORPORATION | ||
| By | /s/ Xxxxxxx X. Xxxxxxx | |
| Title | President and Chief Executive Officer | |
| Address: | ||
| 00000 Xxxxxx Xxxxxx Xxxx Xxxxx 000 Xxxxxx, XX 00000 | ||
| INVESTORS: | ||
| CANAAN EQUITY II L.P. | ||
| By: | Canaan Equity Partners II LLC | |
| By: | /s/ Xxxxx X. Xxxxxxxxx | |
| Member/Manager | ||
| Xxxxx X. Xxxxxxxxx | ||
| Address: | 000 Xxxxxxxx Xxxxxx Xxxxxxxx, XX 00000 | |
| CANAAN EQUITY II L.P. (QP) | ||
| By: | Canaan Equity Partners II LLC | |
| By: | /s/ Xxxxx X. Xxxxxxxxx | |
| Member/Manager | ||
| Xxxxx X. Xxxxxxxxx | ||
| Address: | 000 Xxxxxxxx Xxxxxx Xxxxxxxx, XX 00000 | |
| CANAAN EQUITY II ENTREPRENEURS LLC | ||
| By: | Canaan Equity Partners II LLC | |
| By: | /s/ Xxxxx X. Xxxxxxxxx | |
| Manager | ||
| Xxxxx X. Xxxxxxxxx | ||
| Address: | 000 Xxxxxxxx Xxxxxx Xxxxxxxx, XX 00000 | |
| /s/ Xx. Xxxx Xxxxxxx | ||
| Xx. Xxxx Xxxxxxx | ||
| Address: | Canaan Partners 000 Xxxxxxxx Xxx Xxxxxxxx, XX 00000 | |
| Xxxxxx Living Trust dated 12/10/96 | ||
| By: | /s/ Xxxxx Xxxxxx | |
| Name: | Xxxxx X. Xxxxxx | |
| Title: | Trustee | |
| Address: | 0 Xxxxxxxx Xxxxxx Xxxxxxxx, XX 00000 | |
| /s/ Xxxxxxx Xxxxxxxxxx | ||
| Xxxxxxx Xxxxxxxxxx | ||
| Address: | Canaan Partners 000 Xxxxxxxx Xxx Xxxxxxxx, XX 00000 | |
| CHANNEL MEDICAL PARTNERS, L.P., | ||
| a Delaware limited partnership | ||
| By: | CHANNEL Medical Management, L.L.C. | |
| Its: | General Partner | |
| By: | CHANNEL Medical Advisors, Inc. | |
| Its: | Manager | |
| By: | /s/ W. Xxxxxxx Xxxxxxx | |
| W. Xxxxxxx Xxxxxxx | ||
| President | ||
| Address: | 0000 Xxx Xxxxxxx Xxxx Xxxxx 000 Xxxxxx, XX 00000 | |
| XXXXXXXX VIII | ||
| By: | /s/ Xxxxxx Xxxxxxx | |
| Name: | Xxxxxx Xxxxxxx | |
| Title: | Authorized Signatory | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| XXXXXXXX ASSOCIATES FUND III | ||
| By: | /s/ Xxxxxx Xxxxxxx | |
| Name: | Xxxxxx Xxxxxxx | |
| Title: | Authorized Signatory | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| FEVER TRUST | ||
| By: | /s/ Xxxxx X. Xxxx | |
| Name: | Xxxxx X. Xxxx | |
| Title: | Administrative Trustee | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| FEVER TRUST II | ||
| By: | /s/ Xxxxx X. Xxxx | |
| Name: | Xxxxx X. Xxxx | |
| Title: | Administrative Trustee | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| FEVER TRUST III | ||
| By: | /s/ Xxxxx X. Xxxx | |
| Name: | Xxxxx X. Xxxx | |
| Title: | Administrative Trustee | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| NEW ENTERPRISE ASSOCIATES, VII, LIMITED PARTNERSHIP | ||
| By: | NEA Partners VII, Limited | |
| Partnership | ||
| Its General Partner | ||
| By: | /s/ C. Xxxxxxx Xxxxxxxx | |
| Name: | C. Xxxxxxx Xxxxxxxx | |
| Title: | General Partner | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| NEA PRESIDENTS FUND, L.P. | ||
| By: | NEA General Partners, L.P. | |
| Its General Partner | ||
| By: | /s/ C. Xxxxxxx Xxxxxxxx | |
| Name: | C. Xxxxxxx Xxxxxxxx | |
| Title: | General Partner | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| NEA VENTURES 1997, LIMITED PARTNERSHIP | ||
| By: | /s/ Xxxxx X. Xxxxxxxx | |
| Name: | Xxxxx X. Xxxxxxxx | |
| Title: | Vice President | |
| Address: | 0000 Xxxx Xxxx Xxxx Xxxxx Xxxx, XX 00000 | |
| XXXXX XXXXXXX HEALTHCARE FUND II LIMITED PARTNERSHIP | ||
| By | Xxxxx Xxxxxxx Healthcare Management | |
| Limited Partnership, | ||
| its General Partner | ||
| By: | /s/ Xxxxx X. Xxxxxxx III | |
| Xxxxx X. Xxxxxxx III, | ||
| Vice President of | ||
| Xxxxx Xxxxxxx Ventures, Inc., | ||
| its General Partner | ||
| Address: | Xxxxx Xxxxxxx Ventures, Inc. 000 Xxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxxxxxxx, XX 00000 | |
| VERTICAL FUND I, L.P. | ||
| By | Vertical Group, L.P., General Partner | |
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | President | |
| Address: | 00 XxXxxxxx Xxxxxx Xxxxxx, XX 00000 | |
| VERTICAL FUND II, L.P. | ||
| By | Vertical Group, L.P., General Partner | |
| By: | /s/ Xxxxxxx X. Xxxxx | |
| Name: | Xxxxxxx X. Xxxxx | |
| Title: | President | |
| Address: | 00 XxXxxxxx Xxxxxx Xxxxxx, XX 00000 | |
| MPM BIOVENTURES II, L.P. | ||
| By: | MPM Asset Management II, L.P., | |
| its General Partner | ||
| By: | MPM Asset Management II LLC, | |
| its General Partner | ||
| By: | /s/ Xxxx Xxxxxxx | |
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Investment Manager | |
| Address: | 000 Xxxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 | |
| MPM BIOVENTURES II-QP, L.P. | ||
| By: | MPM Asset Management II, L.P., | |
| its General Partner | ||
| By: | MPM Asset Management II LLC, | |
| its General Partner | ||
| By: | /s/ Xxxx Xxxxxxx | |
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Investment Manager | |
| Address: | 000 Xxxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 | |
| MPM BIOVENTURES GMBH & CO. PARALLEL-BETEILIGUNGS KG | ||
| By: | MPM Asset Management II, L.P., | |
| in its capacity as the | ||
| Special Limited Partner | ||
| By: | MPM Asset Management II LLC, | |
| its General Partner | ||
| By: | /s/ Xxxx Xxxxxxx | |
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Investment Manager | |
| Address: | 000 Xxxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 | |
| MPM ASSET MANAGEMENT INVESTORS 2000 B LLC | ||
| By: | /s/ Xxxx Xxxxxxx | |
| Name: | Xxxx X. Xxxxxxx | |
| Title: | Investment Manager | |
| Address: | 000 Xxxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 | |
| CYCAD GROUP, LLC | ||
| By: | /s/ K. Xxxxxxx Xxxxxx | |
| Name: | K. Xxxxxxx Xxxxxx | |
| Title: | President and Manager | |
| Address: | 0000 Xxxxxxxxxxx Xxxxxx, Xxxxx 000 P.O. Box 5010 Xxxxxxxxxxx, XX 00000 | |
| ev3 INC. | ||
| By: | /s/ Xxx Xxxxxxx | |
| Name: | Xxx Xxxxxxx | |
| Title: | CEO | |
| Address: | c/o Xxx Xxxxxxx 0000 Xxxxxxx Xxxx Xxxxx Xxxx, XX 00000 | |
|
| ||
| Xxxxxxx Xxxxxx, M.D. | ||
| Address: | Cedars-Sinai Medical Towers 0000 X. Xxxxx Xx. #000 Xxxx Xxx Xxxxxxx, XX 00000 | |
| THE XXXXXX LIVING TRUST | ||
|
| ||
| Xxxxxx Xxxxxx, Trustee | ||
| Address: | 000 X. Xxxxxxx Xxxxx Xxxxxxx Xxxxx XX 00000-0000 | |
| XXXXX XXXXXX RESEARCH FOUNDATION | ||
| By: |
| |
| Name: |
| |
| Title: |
| |
| UNICORN MEDICAL INCORPORATED | ||
| By: | /s/ P Xxxxx | |
| Name: | Y P Xxxxx | |
| Title: | CEO | |
| Address: | c/o Xxxxxx Xxxxx, M.D., Department of Radiology Cornell University 000 X. 00xx Xxxxxx Xxx 000 Xxx Xxxx, XX 00000 | |
| PAMALION | ||
| By: | /s/ P Xxxxx | |
| Name: | Y P Xxxxx | |
| Title: | Illegible | |
| Address: | c/o Xxxxxx Xxxxx, M.D., Department of Radiology Cornell University 000 X. 00xx Xxxxxx Xxx 000 Xxx Xxxx, XX 00000 | |
| /s/ P Xxxxx | ||
| Xxxx X. Xxxxx, MD | ||
| Address: | 0 Xxxxxx Xxxxx Xxxxxxxx, XX 00000 | |
| THE XXXXXX OLINS FAMILY TRUST | ||
| /s/ Xxxxx X. Xxxxxx | ||
| Xxxxx X. Xxxxxx, Trustee | ||
| Address: | 0 Xxxxx Xxxx Xxxxxxx Xxxxx, XX 00000 | |
| THE R. XXXXX XXXXXX TRUST DATED MARCH 17, 1999 | ||
| /s/ R. Xxxxx Xxxxxx | ||
| R. Xxxxx Xxxxxx, Trustee | ||
| Address: | 000 X.X. Xxxxxxxxxx Xxxx #000-0 Xxxxx Xxxxxx, XX 00000 | |
| XXXXX X. XXXXXXX AND XXXXXXXXX | ||
| X. XXXXXXX, TRUSTEES OF THE XXXXXXX FAMILY TRUST U/D/T 1/15/86 | ||
| By: | /s/ Xxxxx X. Xxxxxxx /s/ Xxxxxxxxx X. Xxxxxxx | |
| Name: | Xxxxx X. Xxxxxxx Xxxxxxxxx X. Xxxxxxx | |
| Title: | Trustees | |
| Address: | 0000 Xxxx Xxxxxxxx Xxxxx Xxxxxxx Xxxxx, XX 00000 | |
| XXXXXX X. XXXXXXX, TRUSTEE OF THE XXXXXX XXXXX XXXXXXX 1986 TRUST UTA 1/15/86 | ||
| By: | /s/ Xxxxxx X. Xxxxxxx | |
| Name: | Xxxxxx X. Xxxxxxx | |
| Title: | Trustee | |
| Address: | 0000 Xxxx Xxxxxxxx Xxxxx Xxxxxxx Xxxxx, XX 00000 | |
| XXXXXX X. XXXXXXX, TRUSTEE OF THE XXXX XXXXXXX XXXXXXX 1986 TRUST UTA 1/15/86 | ||
| By: | /s/ Xxxxxx X. Xxxxxxx | |
| Name: | Xxxxxx X. Xxxxxxx | |
| Title: | Trustee | |
| Address: | 0000 Xxxx Xxxxxxxx Xxxxx Xxxxxxx Xxxxx, XX 00000 | |
| /s/ R. Xxxxxx Xxxxxxxx III |
||||
| R. Xxxxxx Xxxxxxxx, III | ||||
| Address: | 0000 Xxxxx Xxxxxx | |||
| Xxx Xxxxxxxxx, XX 00000-0000 | ||||
| /s/ Xxxx Xxxxxxxxx Xxxxxxxx |
||||
| Xxxx Xxxxxxxxx Xxxxxxxx | ||||
| Address: | 00 Xxxxxx Xxxxxx | |||
| Xxx Xxxx, XX 00000 | ||||
| /s/ X. X. Xxxxxxxx, Xx. |
||||
| Xxxxxxx X. Xxxxxxxx, Xx. | ||||
| Address: | 0000 Xxxxxxx Xxxxxx | |||
| Xxxx Xxxx, XX 00000 | ||||
| THE WOOD FAMILY TRUST, DATED AUGUST 14, 1998 | ||
| /s/ Xxxxxxx X. Xxxx | ||
| Xxxxxxx X. Xxxx, Co Trustee | ||
| Address: | Wall Street Property Company 000 Xxx Xxxxxxx Xxxxx, Xxxxx 000 Xxxxxxx Xxxxx, XX 00000 | |
EXHIBIT A TO INVESTOR RIGHTS AGREEMENT
(This list does not reflect the conversion of certain shares of Preferred Stock into Common Stock as a result of the investment participation requirements of the Company’s Series F Preferred Stock Financing. This list reflects pre-split shares for all classes and series of stock except the Series F Preferred Stock, which reflects post-split shares.)
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Advent Atlantic & Pacific, L.P. |
3,353 Common | |
| by TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Advent Capital, Ltd. |
873 Common | |
| by Advent International Corporation, General Partner |
||
| Attn: Xxxx Xxxxxxx |
||
| 000 Xxxxxxx Xxxxxx |
||
| Xxxxxx, XX 00000 |
||
| Advent Chestnut II, L.P. |
1,729 Common | |
| by TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Advent Industrial, L.P. |
997 Common | |
| by TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Advent International Investors, L.P. |
41 Common | |
| by Advent International Corporation, General Partner |
||
| Attn: Xxxx Xxxxxxx |
||
| 000 Xxxxxxx Xxxxxx |
||
| Xxxxxx, XX 00000 |
||
| Advent V, L.P. |
6,248 Common | |
| by TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Amerivest, Inc. |
118 Common | |
| Private Equity Investors |
||
| Attn: Xxxxxxx Xxxxxxx, Xx. |
||
| 000 X. 00xx Xxxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxxx X. Xxxxxxxx |
21,609 Common | |
| 0000 X. Xxxxxxxx Xxxx |
||
| Xxxxxxxx Xxxxxx, XX 00000 |
||
| Xxxxxx X. Xxxx, M.D. |
16 Common | |
| 00 Xxxxxxxxx Xxxxxx |
2,000 Series A | |
| Xxxxxx, XX 00000-0000 |
||
| Xxxxxxxx X. Xxxx |
00 Xxxxxx | |
| 0 Xxxxxxx Xxxx |
2,000 Series A | |
| Xxxxxxx, XX 00000 |
161 Series F | |
| Xxxxx X. Xxxxxxxx |
2,415 Series E | |
| 6 South View |
194 Series X | |
| Xxxx xx Xxxx, XX 00000 |
292 Series F | |
| Xxxxxxx Xxxxxxx |
32 Common | |
| Xxxxx Xxxxxxxxxx |
2,894 Common | |
| 0000 Xxxxx Xxxxxx |
22,220 Series A | |
| Xxx Xxxxxxx, XX 00000 |
||
| Xxxxxx Xxxxx |
149 Common | |
| 000 Xxxxxxxx Xxxxx |
||
| Xxx Xxxxxxx, XX 00000 |
||
| The Xxxxxx and Xxxxxx Xxxxx Family Trust |
150 Common | |
| By Its Successor Trustees |
||
| Xxxxxxx Xxxxx |
||
| 000 X. Xxxxxx Xxxxxx |
||
| Xxx Xxxxxxx, XX 00000 and |
||
| Xxxx Xxxxx |
||
| 00000 Xxxxxx Xxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Xxxx & Co. |
1,533 Common | |
| (Nominee Name for Chestnut Capital International II) |
||
| By TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Boston Safe Deposit and Trust Company as Trustee for |
303 Common | |
| US WEST Master Trust |
||
| Attn: Xx. Xxxxxxxxx Xxxxx |
||
| 0 Xxxxx Xxxx |
||
| Xxxxxxx, XX 00000-0000 |
||
| Xxxxxxx, Phleger & Xxxxxxxx LLP |
12,077 Series E | |
| 00 Xxxxxxxxxx Xxxxx |
||
| Xxxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Channel Medical Partners, L.P. |
666,667 Series F | |
| 0000 Xxx Xxxxxxx Xxxx, Xxxxx 000 |
||
| Xxxxxx, XX 00000 |
||
| Xxxxxx X. Xxxxx |
1,538 Common | |
| 0000 X. Xxxxx Xxxxxx Xxxxxxx |
||
| Xxxxx 000 |
||
| Xxxxxxxxx, XX 00000 |
||
| Xxxxxx X. and Xxxxxxx X. Xxxxx, |
6,750 Common | |
| as Community Property |
12,000 Series A | |
| 0000 X. Xxxxx Xxxxxx Xxxxxxx |
5,835 Series B | |
| Xxxxx 000 |
||
| Xxxxxxxxx, XX 00000 |
||
| Canaan Equity II L.P. |
1,289,040 Series F | |
| 000 Xxxxxxxx Xxxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Canaan Equity II L.P. (QP) |
576,624 Series F | |
| 000 Xxxxxxxx Xxxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Canaan Equity II Entrepreneurs LLC |
102,336 Series F | |
| 000 Xxxxxxxx Xxxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| PaineWebber FBO Xxxxxx X. Xxxxx |
3,000 Common | |
| 00 X. Xxx Xxxxxxxx |
||
| Xxxxx 000 |
||
| Xxx Xxxx, XX 00000 |
||
| CMI Ventures |
31 Common | |
| c/o Xxxxxxx Xxxxx |
||
| 0000 Xxxxxxxx Xxxxxx |
||
| Xxxx Xxxx, XX 00000 |
||
| R. Xxxxx Xxxxxx, Trustee under |
30,180 Common | |
| R. Xxxxx Xxxxxx Trust |
90,000 Series A | |
| 000 XX Xxxxxxxxxx Xxxx |
23,341 Series B | |
| #307-8 South |
13,517 Series F | |
| Xxxxxx, Xxxxxxx 00000 |
||
| Xxxxxxx Street Fund c/o Xxxxx Xxxxxx |
||
| 0 Xxxxxxxx Xxxx |
||
| Xxxxxxx, XX 00000 |
||
| Xxxxx Xxxxx |
364 Common | |
| 000 X. Xxxxxxx Xxxxx #00 |
2,000 Series A | |
| Xxxxxxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxxx Xxxxxx, Trustees of |
302,089 Common | |
| The Corday Living Trust |
224,000 Series A | |
| 000 X. Xxxxxxx Xxxxx |
136,158 Series B | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| The Xxxxx Xxxxxx Research Foundation |
9,278 Common | |
| c/o Xxxxx Xxxxxx |
163,239 Series B | |
| 000 X. Xxxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxxx Xxxxxx, M.D. |
43,192 Common | |
| Cedars-Sinai Medical Towers |
5,489 Series B | |
| 0000 X. Xxxxx Xx. #000 West |
30 Series F | |
| Xxx Xxxxxxx, XX 00000 |
||
| Xxxxxx X. Xxxxxxx, Trustee of |
1,127 Common | |
| the Xxxxxx Xxxxx Xxxxxxx 1986 |
40,000 Series A | |
| Trust UTA 1/15/86 |
5,161 Series F | |
| 0000 Xxxx Xxxxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxx X. Xxxxxxx, Trustee of |
1,127 Common | |
| the Xxxx Xxxxxxx Xxxxxxx 1986 |
40,000 Series A | |
| Trust UTA 1/15/86 |
11,828 Series F | |
| 0000 Xxxx Xxxxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxx X. Xxxxxxx and Xxxxxxxxx X. Xxxxxxx, Trustees |
45,727 Common | |
| of the Xxxxxxx Family Trust U/D/T 1/15/86 |
75,000 Series A | |
| 0000 Xxxx Xxxxxxxx Xxxxx |
9,677 Series F | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxxx Xxxxxx |
7 Common | |
| 0000 Xxxxxxx Xxxx |
||
| Xxxxxx Xxxxxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxxx Trust U/D/T dated 7/12/87 |
5,472 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Cycad Group, LLC |
60,750 Common | |
| c/o K. Xxxxxxx Xxxxxx, Esq. |
111,108 Series A | |
| 0000 Xxxxx Xxxxxxx Xxxx |
51,445 Series B | |
| Suite K |
57,283 Series X | |
| Xxxxx Xxxxxxx, XX 00000-0000 |
116,084 Series F | |
| 43,912 Series F | ||
| Xxxxx Deyhiny (Xxxxxxx) |
724 Series E | |
| J. Xxxxx Xxxxx |
125 Common | |
| 0000 X. Xxxxx Xxxxxx |
||
| Xxx Xxxxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxxx Xxxxxxx |
172 Common | |
| Chairman, Department of Radiology |
||
| Northwestern University |
||
| 000 X. Xxxxxxxx, Xxx 000 |
||
| Xxxxxxx, XX 00000 |
||
| Xxxxx Xxxxxxx |
172 Common | |
| c/o Xxxxxx Xxxxxxx, M.D. |
||
| Chairman, Department of Radiology |
||
| Northwestern University |
||
| 000 X. Xxxxxxxx, Xxx 000 |
||
| Xxxxxxx, XX 00000 |
||
| ev3 Inc. |
3,864,734 Series E | |
| c/o Xxx Xxxxxxx |
208,340 Series F | |
| 0000 Xxxxxxx Xxxx |
||
| Xxxxx Xxxx Xxxx, XX 00000 |
||
| Xxxxx X. Xxxxx |
1,000 Series A | |
| 0000 Xxxxxxx Xxxx Xxxxx |
||
| Xxxxx Xxx, XX 00000 |
||
| Xxxxxx X. Xxxxx |
1,000 Series A | |
| 0000 Xxxx Xxxxx Xxxxx |
||
| Xxxxxxxxxx, XX 00000 |
||
| Xxxx Xxxxxx, M.D. |
125 Common | |
| 00 Xxx Xxxxxxxx |
||
| Xxxxx, 00000 |
||
| Xxxxxx |
||
| The Xxxxxx Olins Family Trust |
2,595 Series E | |
| Attn: Xxxxx Xxxxxx, Trustee |
310 Series F | |
| 8 Tidal Surf |
000 Xxxxxx X | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Fever Trust |
422,706 Series E | |
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Fever Trust II |
15,938 Series E | |
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Fever Trust III |
65,018 Series F | |
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Xxxxxxx X. Xxxx |
4,830 Series E | |
| P.O. Box 1491 |
387 Series F | |
| Xxx Xxxxx, XX 00000 |
292 Series F | |
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxx X. Xxxxx |
13 Common | |
| Xxxxxxx Capital Corp. |
||
| 0 Xxxxxx Xxxx |
||
| Xxxxxxxxxx, XX 00000 |
||
| Xxxxx X. Xxxxxxx |
150 Common | |
| 0000 Xxxxx Xxxx Xxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| Xxxxxx Xxxxx M.D. |
19,355 Series C-D | |
| Department of Radiology |
19,323 Series E | |
| Cornell University |
8,333 Series F | |
| 000 X. 00xx Xxxxxx, Xxx 000 |
||
| Xxx Xxxx, XX 00000 |
||
| Xxxxxxx Co., Ltd. |
1,046 Common | |
| 00000-X Xxxxxxx Xxxxxx |
||
| Attn: Xxxxx Xxxxxxxx |
||
| Xxxxxxxxxx Xxxxx, XX 00000 |
||
| Guidant Corporation |
621,746 Series C-D | |
| 000 Xxxxxxxxxxxx Xxxxx |
1,124,617 Series C-D | |
| Xxxxx Xxxx, XX 00000 |
||
| Xxxx & Co. (nominee name for Citibank, N.A., |
241 Common | |
| as Custodian for Citicare at the direction of |
||
| Chancellor Capital Management, Inc., Investment Manager) |
||
| UNKNOWN (No longer a Chancellor client) |
||
| Health Care Ventures, Inc. |
37,923 Common | |
| c/o Xxxxxx X. Xxxxxxxx |
||
| 0000 X. Xxxxxxxx Xxxx |
||
| Xxxxxxxx Xxxxxx, XX 00000 |
||
| Xxx X. Xxxx |
3 Common | |
| Technology Crossover Ventures |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 000 |
||
| Xxxx Xxxx, XX 00000 |
||
| Xxxxxx X. Xxxxxxx |
000 Xxxxxx | |
| 00 Xxxxxx Xxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Xxxxxx Living Trust dated 12/10/96 |
25,122 Series E | |
| 0 Xxxxxxxx Xxxxxx |
2,996 Series F | |
| Xxxxxxxx, XX 00000 |
20,000 Series F | |
| Xxxxxx Xxxxxxx |
280 Common | |
| 0000 Xxxxxx Xxxx Xxxx |
||
| Xxx Xxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Kaneko Enterprises, Inc. |
6,771 Common | |
| 00000-X Xxxxxxx Xxxxxx |
||
| Attn: Xxxxxxxx Xxxxxx |
||
| Xxxxxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxx Kar |
2,000 Common | |
| 000 Xxxxx Xxxxxxxx Xxxxxx #0X |
||
| Xxx Xxxxxxx, XX 00000 |
||
| Xxxxxxx Xxxxxxxxxx |
8,333 Series F | |
| 000 Xxxxxxxx Xxxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxx |
8,501 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxx |
11,834 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxx Xxxxxx Xxxxxxx |
23,937 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
1,324 Series A | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxx X. Xxxxxxx, Custodian for Xxxxxxx X. Xxxxxxx |
3,685 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
220 Series A | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxx X. Xxxxxxx, Custodian for Xxxxxxx X. Xxxxxxx |
351 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
220 Series A | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxx X. Xxxxxxx |
701 Common | |
| 000 Xxxxx Xxxxxx Xxxxx |
440 Series A | |
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxx Xxxx |
63 Common | |
| 000 Xxxxx Xxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxxxxxxx Xxxxxxxxx |
1,052 Common | |
| 000 Xxxxxxx Xxxxxxx |
||
| Xxxxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxxxx |
6,313 Common | |
| X.X. Xxx 0000 |
||
| Xxxxxx Xxxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxxxx |
188 Common | |
| c/o Xxxxxxx X. Xxxxxxxxx |
||
| X.X. Xxx 0000 |
||
| Xxxxxx Xxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxxxxx VIII |
940,264 Series C-D | |
| 0000 Xxxx Xxxx Xxxx |
2,440,769 Series C-D | |
| Xxxxx Xxxx, XX 00000 |
936,685 Series C-D | |
| 481,427 Series E | ||
| 756,404 Series F | ||
| Xxxxxxxx Associates Fund III |
49,488 Series C-D | |
| 0000 Xxxx Xxxx Xxxx |
128,463 Series C-D | |
| Xxxxx Xxxx, XX 00000 |
49,299 Series C-D | |
| 25,339 Series E | ||
| 39,810 Series F | ||
| Medtronic, Inc. |
54,000 Common | |
| 000 Xxxxxxxxx Xxxxxxx |
535,452 Series A | |
| Xxxxxxxxxxx, XX 00000 |
301,299 Series B | |
| 994,706 Series C-D | ||
| 340,071 Series C-D | ||
| 415,459 Series E | ||
| Medtronic Asset Management, Inc. |
270,000 Common | |
| 000 Xxxxxxxxx Xxxxxxx |
||
| Xxxxxxxxxxx, XX 00000 |
||
| Mellon Bank, N.A. |
19 Common | |
| Master Trustee for Xxxx Atlantic Master Trust |
||
| (as directed by Chancellor Capital Management, Inc., |
||
| Investment Manager) |
||
| UNKNOWN (No longer a Chancellor client) |
||
| Mellon Bank, N.A. |
303 Common | |
| Master Trustee for Xxxx Atlantic Master Trust |
||
| (as directed by Citibank, N.A., Investment Manager) |
||
| UNKNOWN (No longer a Chancellor client) |
||
| Xxxxx Xxxxxx |
1,000 Series A | |
| Endicor Medical, Inc. |
80 Series F | |
| 0000 Xxxxxxx Xxxxxxx |
||
| Xxxxx X |
||
| Xxxxxxxx, XX 00000 |
||
| MPM Bioventures II, L.P. |
565,494 Series E | |
| c/o Xxxx Xxxxxxx |
199,886 Series F | |
| 000 Xxxxxxxxxx Xxxxxx |
||
| 00xx Xxxxx |
||
| Xxxxxx, XX 00000 |
||
| MPM Bioventures II-QP, L.P. |
5,123,691 Series E | |
| c/o Xxxx Xxxxxxx |
1,811,086 Series F | |
| 000 Xxxxxxxxxx Xxxxxx |
||
| 00xx Xxxxx |
||
| Xxxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| MPM Bioventures GMBH & Co. Parallel-Beteiligungs KG |
1,803,795 Series E | |
| c/o Xxxx Xxxxxxx |
637,592 Series F | |
| 000 Xxxxxxxxxx Xxxxxx |
||
| 00xx Xxxxx |
||
| Xxxxxx, XX 00000 |
||
| MPM Asset Management Investors 2000 B LLC |
117,970 Series E | |
| c/o Xxxx Xxxxxxx |
41,699 Series F | |
| 000 Xxxxxxxxxx Xxxxxx |
||
| 00xx Xxxxx |
||
| Xxxxxx, XX 00000 |
||
| New Enterprise Associates VII, Limited Partnership |
933,047 Series C-D | |
| 0000 Xxxx Xxxx Xxxx |
2,569,232 Series C-D | |
| Xxxxx Xxxx, XX 00000 |
985,984 Series C-D | |
| 1,009,501 Series E | ||
| 844,489 Series F | ||
| NEA Presidents Fund, L.P. |
51,550 Series C-D | |
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| NEA Ventures 1997, Limited Partnership |
5,155 Series C-D | |
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Pamalion |
60,000 Series F | |
| c/o Xxxx Xxxxx, M.D. |
||
| 00, xxx xx Xxxxxxx |
||
| 00000 Xxxxxxxx-Xx-Xxx, Xxxxxx |
||
| Pantheon USA Fund Limited |
244 Common | |
| Attn: Xxx Xxxx |
||
| 00 Xxxxxxxxxx Xxxxxx, Xxxxx 000 |
||
| Xxx Xxxxxxxxx, XX 00000 |
||
| Xxxxx & Xxxx Xxxxxxxx |
152 Common | |
| 0000 Xxxxxx Xxxx |
||
| Xxxxxx, XX 00000 |
||
| Xxxxx Xxxxxxx Healthcare Fund II Limited Partnership |
1,384,616 Series X-X | |
| Xxxxx Jaffray Ventures, Inc. |
417,224 Series C-D | |
| 000 Xxxxx Xxxxxx, Xxxxx 0000 |
347,827 Series X | |
| Xxx Xxxxxxxxx, XX 00000 |
290,805 Series F | |
| Pitt & Co. |
321 Common | |
| c/o Bankers Trust Company |
||
| GFS/CTAG Bin #4 Window #43 |
||
| 00 Xxxx Xxxxxx - 0xx Xxxxx |
||
| Attn: Xxxxxxxx Xxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| Xxxxxxxx Xxx |
000 Xxxxxx | |
| X.X. Xxx 000000 |
||
| Xxxxxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxx X. Pound |
808 Common | |
| 00000 Xxxxxxx |
||
| Xxxxxx Xxxxx, XX 00000 |
||
| Private Equity Investment Fund, L.P. |
17 Common | |
| Attn: Xxxxxxx Xxxxxxx, Xx. |
||
| 000 X. 00xx Xxxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| Xxxxxxx and Xxxx Xxxxxxx |
3,000 Series A | |
| Xxxxxxx Xxxxx, under GUGMA |
32 Common | |
| Until age 18 |
||
| Xxxxx Xxxxx |
32 Common | |
| Xxxxx Family Trust U/D/T |
63 Common | |
| Dated 12/19/88 |
||
| Rovent Limited Partnership |
3,062 Common | |
| By Advent International Limited Partnership, General Partner |
||
| By Advent International Corporation, General Partner |
||
| Attn: Xxxx Xxxxxxx |
||
| 000 Xxxxxxx Xxxxxx |
||
| Xxxxxx, XX 00000 |
||
| Xx. Xxxx Xxxxxxx |
12,000 Series F | |
| 000 Xxxxxxxx Xxxxxx |
||
| Xxxxxxxx, XX 00000 |
||
| Saturn & Co. TID04-2457313 |
798 Common | |
| by TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Xxxxx Xxxxxx |
5 Common | |
| Chancellor Capitol Management, Inc. |
||
| Managing Director |
||
| 1166 Avenue of the Americas |
||
| Attn: Xxxx Xxxxxxxxxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| Sequoia Capital IV |
33,872 Common | |
| c/o Sequoia Technology Partners |
||
| Xxxxxxxx 0, Xxxxx 000 |
||
| 0000 Xxxx Xxxx Xxxx |
||
| Attn: Xxxxxx Xxxxxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Sequoia Technology Partners II |
2,259 Common | |
| c/o Sequoia Technology Partners |
||
| Xxxxxxxx 0, Xxxxx 000 |
||
| 0000 Xxxx Xxxx Xxxx |
||
| Attn: Xxxxxx Xxxxxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Sequoia XX |
273 Common | |
| c/o Sequoia Technology Partners |
||
| Xxxxxxxx 0, Xxxxx 000 |
||
| 0000 Xxxx Xxxx Xxxx |
||
| Attn: Xxxxxx Xxxxxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Sequoia XXI |
1,233 Common | |
| Xxxxxxxx 0, Xxxxx 000 |
||
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Xxxxxx X. Xxxx |
2 Common | |
| Chancellor Capital Management |
||
| 0000 Xxxxxx xx xxx Xxxxxxxx |
||
| Xxx Xxxx, XX 00000 |
||
| Xxxxxx Xxxx |
8 Common | |
| Xxxxxx Xxxxxxxx |
131 Common | |
| 0000 Xxxxxx Xxxx |
||
| Xxx Xxxxx, XX 00000 |
||
| Xxxx Xxxxxxx |
47 Common | |
| Xxxxx X. Xxxxxx |
940 Common | |
| 35 Xxxxx Xxxxx |
8,000 Series A | |
| Xxxxxx Xxxxx Xxxxxxxxx, XX 00000 |
||
| Xxxxxxx Silk |
2,000 Common | |
| Cedars Sinai Medical Towers |
||
| 0000 X. Xxxxx Xxxxxx, #000 Xxxx |
||
| Xxx Xxxxxxx, XX 00000 |
||
| Xxxx Xxxxxx |
3,334 Common | |
| 0000 Xxxx Xxxxxx Xxxxx |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Stanford University |
388 Common | |
| Stanford Management Office |
||
| Attn: Xxxxx Xxxxxx |
||
| 0000 Xxxx Xxxx Xxxx |
||
| Xxxxx Xxxx, XX 00000 |
||
| Xxxxx X. and Xxxxxxxxx Xxxxx, Trustees |
3,584 Common | |
| FBO The Xxxxx Family Trust U/A Dated 6/4/84 |
||
| 0000 Xxxxxxx Xxxxx |
||
| Xxx Xxxxx, XX 00000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxx X. Xxxxxxx |
207 Common | |
| 000 Xxxxxxxx Xxxx |
8,000 Series A | |
| Xxxxxxxxx, XX 000000 |
||
| TA Investors |
145 Common | |
| By TA Associates |
||
| Attn: Xxxxxxxxx X. Xxxxxxxx |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 0000 |
||
| Xxxxxx, XX 00000 |
||
| Xxxxxx Xxxxxx-Hornoch |
1,383 Common | |
| 0 Xxxxxxxxx Xxxxx, Xxx. #000 |
||
| Xxxxxxxxxx, XX 00000 |
||
| Xxxx Xxxxxx |
3 Common | |
| Technology Crossover Ventures |
||
| 000 Xxxx Xxxxxx |
||
| Xxxxx 000 |
||
| Xxxx Xxxx, XX 00000 |
||
| Xxxx Xxxxxx |
30,000 Common | |
| 0 Xxxxxxxxx Xxxx |
||
| Xxxxxxxxx Xxxxxxxx, XX 00000 |
||
| Unicorn Medical Inc. |
76,924 Series C-D | |
| c/o Xxxxxx Xxxxx, M.D. |
14,492 Series E | |
| Department of Radiology |
6,666 Series F | |
| Cornell University |
||
| 000 X. 00xx Xxxxxx, Xxx 000 |
||
| Xxx Xxxx, XX 00000 |
||
| Vertical Fund I, L.P. |
466,154 Series C-D | |
| 00 XxXxxxxx Xxxxxx |
361,471 Series C-D | |
| Xxxxxx, XX 00000 |
210,858 Series E | |
| 196,914 Series F | ||
| 127,258 Series F | ||
| Vertical Fund II, L.P. |
149,231 Series C-D | |
| 00 XxXxxxxx Xxxxxx |
115,718 Series C-D | |
| Summit, NJ 0790 |
62,894 Series E | |
| 47,326 Series F | ||
| 30,827 Series F | ||
| Xxxxxxx Xxxxxxxxxx |
3 Common | |
| 0000 Xxxxxxxxx # 000 |
||
| Xxxxxx Xxxxx, XX 00000 |
||
| Xxxx Xxxxxx |
483 Series E | |
| Xxxx X. Xxxxx |
66 Common | |
| 00000 Xxxxxxxxxx Xxxxxxx |
||
| #X000 |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
| Xxxx X. Xxxxxxxxx |
13,542 Common | |
| 00000 Xxxxx Xxxxxx |
||
| Xxxxxxxxxx Xxxxx, XX 00000-0000 |
||
| NAME & ADDRESS OF INVESTOR |
REGISTRABLE SECURITIES | |
| Xxxxxxx X. Xxxxxxxx and Xxxxx Xxxxxx Xxxxxxxx |
22,313 Common | |
| 0000 Xxxxxxx Xxxxxx |
||
| Xxxx Xxxx, XX 00000 |
||
| Xxxxxxx X. Xxxxxxxx, Xx. |
225,217 Common | |
| 0000 Xxxxxxx Xxxxxx |
177,776 Series A | |
| Xxxx Xxxx, XX 00000 |
211,228 Series B | |
| 13,300 Series F | ||
| 6,733 Series F | ||
| R. Xxxxxx Xxxxxxxx, III |
165,610 Common | |
| 0000 Xxxxx Xxxxxx |
133,332 Series A | |
| Xxx Xxxxxxxxx, XX 00000-0000 |
131,506 Series B | |
| 8,587 Series F | ||
| 4,391 Series F | ||
| Xxxx Xxxxxxxxx Xxxxxxxx |
165,610 Common | |
| 00 Xxxxxx Xxxxxx |
133,332 Series A | |
| Xxx Xxxx, XX 00000 |
131,506 Series B | |
| 8,587 Series F | ||
| 4,391 Series F | ||
| Xxxxxxxxx X. Xxxxx |
2,415 Series E | |
| 00 Xxxxxxxxxx Xxxxx |
194 Series F | |
| Xxxxxx, XX 00000 |
292 Series F | |
| Xxxxxx Xxxx |
16 Common | |
| Xxxxxxxxx, Xxxxxxxx & Company |
||
| 000 Xxxxxxxxxx Xxxxxx, #0000 |
||
| Xxx Xxxxxxxxx, XX 00000 |
||
| WS Investments 85A |
50 Common | |
| Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx |
||
| 000 Xxxx Xxxx Xxxx |
||
| Xxxx Xxxx, XX 00000 |
||
| WS Investments 86A |
10 Common | |
| Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx |
||
| 000 Xxxx Xxxx Xxxx |
||
| Xxxx Xxxx, XX 00000 |
||
| WS Investments 92B |
22,212 Series A | |
| Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx |
||
| 000 Xxxx Xxxx Xxxx |
||
| Xxxx Xxxx, XX 00000 |
||
| WTI Ventures |
9,415 Common | |
| Attn: S. Xxxxx Xxxxxxx |
||
| 0000 Xxxxx Xxxxxx, Xxxx 000 |
||
| Xxxxx Xxxx, XX 00000 |
||
| The Wood Family Trust, |
20,000 Series F | |
| Xxxxxxx X. Xxxx, Co Trustee |
||
| Wall Street Property Company |
||
| 000 Xxx Xxxxxxx Xxxxx, Xxxxx 000 |
||
| Xxxxxxx Xxxxx, XX 00000 |
||
EXHIBIT B
COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT
The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor Rights Agreement, dated as of September , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder.
All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement.
The undersigned has executed this Counterpart to the Investor Rights Agreement as of 9/21, 2004.
| Xxxxxxx X. Xxxx | ||
| (Print name of individual or company) | ||
| Sign: | /s/ Xxxxxxx X. Xxxx | |
| Title (if applic.): |
| |
| Address: | ||
| XX Xxx 0000 Xxx Xxxxx, XX 00000 | ||
| Tel. no.: | 000-000-0000 | |
| Fax no.: | 000-000-0000 | |
EXHIBIT B
COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT
The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor Rights Agreement, dated as of September , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder.
All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement.
The undersigned has executed this Counterpart to the Investor Rights Agreement as of Oct. 1, 2004.
| Xxxxxxxxx X. Xxxxx | ||
| (Print name of individual or company) | ||
| Sign: | /s/ Xxxxxxxxx X. Xxxxx | |
| Title (if applic.): |
| |
| Address: | ||
| 00 Xxxxxxxxxx Xxxxx Xxxxxx, XX 00000 | ||
| Tel. no.: | 000 000-0000 | |
| Fax no.: | ||
EXHIBIT B
COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT
The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor Rights Agreement, dated as of September , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder.
All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement.
The undersigned has executed this Counterpart to the Investor Rights Agreement as of , 200 .
| Xxxxx X. Xxxxxxxx | ||
| (Print name of individual or company) | ||
| Sign: | /s/ Xxxxx Xxxxxxxx | |
| Title (if applic.): |
| |
| Address: | ||
| 0 Xxxxx Xxxx Xxxx xx Xxxx, XX 00000 | ||
| Tel. no.: | 949/ 000-0000 | |
| Fax no.: | 949/ 000-0000 | |
